Panion & Bf Biotech Inc. (TPE:1760)
Taiwan · Delayed Price · Currency is TWD 61.60
-0.70 (-1.12%)
Feb 11, 2026, 1:30 PM CST
Panion & Bf Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 2,040 | 2,030 | 1,882 | 2,399 | 1,901 | 1,569 | |
Revenue Growth (YoY) | 0.20% | 7.85% | -21.54% | 26.16% | 21.20% | -0.34% |
Cost of Revenue | 943.58 | 959.37 | 907.48 | 1,080 | 989.07 | 754.61 |
Gross Profit | 1,096 | 1,070 | 974.4 | 1,319 | 912.14 | 814.03 |
Selling, General & Admin | 607.48 | 618.22 | 601.58 | 656.06 | 587 | 560.16 |
Research & Development | 200.13 | 236.88 | 217.04 | 248.5 | 157.71 | 127.02 |
Other Operating Expenses | 0 | 9.84 | - | - | - | 18.91 |
Operating Expenses | 806.62 | 864.61 | 817.57 | 904.63 | 746.8 | 709.53 |
Operating Income | 289.6 | 205.67 | 156.83 | 413.96 | 165.34 | 104.5 |
Interest Expense | -14.69 | -15.02 | -11.36 | -7.59 | -14.68 | -4.47 |
Interest & Investment Income | 5.23 | 10.46 | 11.19 | 4.77 | 7.02 | 6.27 |
Earnings From Equity Investments | 0.43 | -8.44 | -14.02 | -8.18 | -12.17 | -13.13 |
Currency Exchange Gain (Loss) | -8.2 | 11.95 | -2.97 | -0.32 | -3.07 | -16.9 |
Other Non Operating Income (Expenses) | 3.1 | 10.77 | 21.33 | 17.55 | 33.84 | 7.17 |
EBT Excluding Unusual Items | 275.47 | 215.39 | 161.01 | 420.2 | 176.28 | 83.45 |
Gain (Loss) on Sale of Investments | -0.98 | 1.46 | 7.5 | -93.68 | 6.72 | 5.79 |
Gain (Loss) on Sale of Assets | -0.13 | -0.1 | -0.38 | 6.28 | -0.44 | - |
Other Unusual Items | 0.69 | 0.69 | 0.58 | 0.61 | 0.08 | 0.17 |
Pretax Income | 275.05 | 217.44 | 168.71 | 333.41 | 182.65 | 89.41 |
Income Tax Expense | 100.68 | 92.91 | 91.49 | 151.06 | 78.25 | 61.51 |
Earnings From Continuing Operations | 174.37 | 124.52 | 77.22 | 182.35 | 104.4 | 27.9 |
Net Income | 174.37 | 124.52 | 77.22 | 182.35 | 104.4 | 27.9 |
Net Income to Common | 174.37 | 124.52 | 77.22 | 182.35 | 104.4 | 27.9 |
Net Income Growth | 43.71% | 61.26% | -57.65% | 74.66% | 274.19% | -82.71% |
Shares Outstanding (Basic) | 86 | 86 | 86 | 86 | 79 | 77 |
Shares Outstanding (Diluted) | 86 | 86 | 86 | 86 | 79 | 77 |
Shares Change (YoY) | 0.04% | 0.01% | -0.04% | 8.32% | 3.18% | -0.06% |
EPS (Basic) | 2.03 | 1.45 | 0.90 | 2.13 | 1.32 | 0.36 |
EPS (Diluted) | 2.03 | 1.45 | 0.90 | 2.12 | 1.32 | 0.36 |
EPS Growth | 43.45% | 61.11% | -57.55% | 60.78% | 266.26% | -82.86% |
Free Cash Flow | 169.23 | 165.49 | -3.81 | 291.23 | 231.22 | -115.72 |
Free Cash Flow Per Share | 1.97 | 1.93 | -0.04 | 3.39 | 2.92 | -1.51 |
Dividend Per Share | 1.800 | 1.800 | 1.500 | 2.000 | 1.500 | 0.700 |
Dividend Growth | 20.00% | 20.00% | -25.00% | 33.33% | 114.29% | -61.11% |
Gross Margin | 53.74% | 52.73% | 51.78% | 54.97% | 47.98% | 51.89% |
Operating Margin | 14.20% | 10.13% | 8.33% | 17.26% | 8.70% | 6.66% |
Profit Margin | 8.55% | 6.13% | 4.10% | 7.60% | 5.49% | 1.78% |
Free Cash Flow Margin | 8.30% | 8.15% | -0.20% | 12.14% | 12.16% | -7.38% |
EBITDA | 406.45 | 341.73 | 298.19 | 546.26 | 275.7 | 160.18 |
EBITDA Margin | 19.93% | 16.84% | 15.85% | 22.77% | 14.50% | 10.21% |
D&A For EBITDA | 116.85 | 136.06 | 141.36 | 132.29 | 110.36 | 55.68 |
EBIT | 289.6 | 205.67 | 156.83 | 413.96 | 165.34 | 104.5 |
EBIT Margin | 14.20% | 10.13% | 8.33% | 17.26% | 8.70% | 6.66% |
Effective Tax Rate | 36.61% | 42.73% | 54.23% | 45.31% | 42.84% | 68.79% |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.